Annual Kidney Cancer UK Survey report highlights urgent need for earlier detection and NHS care pathway overhaul
- New data from Kidney Cancer UK reveals that one in five (20%) kidney cancer patients are being diagnosed at stage 4 – resulting in harsher treatments, reduced quality of life, and significantly higher mortality rates.
- Late detection of the disease can be attributed to notoriously vague or absent symptoms, leaving patients dismissed or misdiagnosed until the disease has advanced.
- This Kidney Cancer Awareness Week (2–6 February), the charity is calling for the development of a primary care test for earlier detection; greater GP support, awareness and training – as well as widespread implementation of the first NICE guidelines for kidney cancer, due to be published in Spring 2026.
CLICK to read
Monday, 2nd February 2026: Today, Kidney Cancer UK publishes the results of its 12th annual patient survey*, revealing the stark reality of a kidney cancer diagnosis in the UK. The findings of the report show that one in five (20%) kidney cancer patients are now diagnosed at the most advanced stage of the disease, reflecting the growing mortality rate over recent decades, increasing by 73% since the 1970s.
Research shows that approximately three-quarters (74–75%) of people diagnosed with stage 3 kidney cancer survive for at least five years, though for those diagnosed at stage 4, when the cancer has spread to distant organs, five-year survival falls significantly to around 10–15%. The 5-year survival rates in the UK are among the lowest in Europe.**
Kidney cancer now ranks as the UK’s sixth most common cancer with around 13,800 new cases each year – that’s roughly 38 new diagnoses every day. Around 4,700 people die from the disease annually, amounting to about 13 deaths per day.
The latest report from Kidney Cancer UK evidences the need for an overhaul of the kidney cancer care pathway, in line with the imminent introduction of the NICE (National Institute for Health and Care Excellence) guideline, which the charity campaigned NHS England for in Spring 2026 – will define the quality agenda for kidney cancer services moving forward.
Additionally, the ongoing National Kidney Cancer Audit will play a unique and vital role in measuring resulting service quality improvements for patients to regularly monitor progress.
(1) The challenge of late-stage diagnosis.
One of the greatest challenges with kidney cancer is that early-stage disease (stages one and two) is almost entirely symptom-free. As a result, there are often no warning signs to indicate cancer is present unless investigations are carried out for an unrelated reason.
This creates significant difficulties for both patients and clinicians, frequently leading to delays in seeking medical advice and, in some cases, an initial misdiagnosis.
Historically, NICE guidance on suspected kidney cancer has been highly restrictive, identifying haematuria (blood in the urine) as the sole indicative symptom.
The annual survey findings from Kidney Cancer UK have consistently shown that the picture is far more complex when it comes to signs and symptoms.
When looking at the time from first feeling unwell and seeking medical advice to receiving a diagnosis, the survey results show almost a third (32%) of patients waited more than 3 months – virtually no improvement from the previous year (34%).
In the period before referral for diagnosis, more than one in four (26%) patients are initially diagnosed with a different condition, a marked increase on the previous year (21%). This adds to the overall time it takes for a diagnosis to be made.
The survey also found that in patients diagnosed at stages 1-3, the most common symptoms reported were pain in the back/flank/side (34%), blood in urine (28%), and fatigue (24%). However, notably, 29% reported no symptoms at all.
In patients diagnosed at stage 4, the most common symptoms reported were pain in the back/flank/side (37%), fatigue (34%), blood in urine (26%), and weight loss (26%). Of these patients, 15% still reported no symptoms at all.
One in five (20.34%) kidney cancer patients waited over 3 months to a year from feeling unwell before they sought medical advice, and a quarter (26.31%) of patients received an initial misdiagnosis, further delaying an accurate diagnosis that can be appropriately treated, influencing patient outcomes.
(2) The impact.
Patients report feeling ‘dismissed’ when symptoms are attributed to benign causes – commonly conditions such as kidney stones or UTIs – only to later discover kidney cancer, contributing to the percentage of late-stage diagnoses.
Whilst the survey reveals the high percentage of kidney cancer patients diagnosed at stage 4, it also reveals that over a quarter (28.21%) are diagnosed at stage 3.
There has also been no improvement in last year’s results in the occurrence of patients being diagnosed by chance, with over half (54%) of patients being diagnosed incidentally during scans for unrelated conditions.
The survey has also highlighted the increased anxiety and fear of recurrence among those living with and beyond kidney cancer. With over two-fifths (42.02%) reporting feeling scared of the cancer reoccurring.
(3) What needs to change.
In order for outcomes to improve for kidney cancer patients, Kidney Cancer UK is calling for:
- A clear, government-funded research strategy to develop a simple, inexpensive test for use in primary care. There is the persistent challenge of how to identify people with kidney cancer early. Currently, there’s no simple blood test or easy method of early detection. Within the next three years, the charity hopes to see a much more focused and strategic effort around research into early-stage kidney cancer – particularly into identifying biomarkers that could be measured easily.
- Improved decision support software with stronger prompts and flags for primary care, such as GPs, to identify suspected kidney cancer. This also links back to the implementation of NICE guidelines for kidney cancer.
- Better guidance, training, and awareness for GPs and healthcare professionals
- These measures could transform diagnosis, save lives, and ensure patients receive timely, appropriate care.
Professor Grant Stewart, Professor of Surgical Oncology at the University of Cambridge and Consultant Urologist at Addenbrooke’s Hospital, Cambridge, says:
The finding that just over 20% of patients are now being diagnosed with stage 4 kidney cancer represents a concerning year-on-year increase. Kidney cancer often presents with non-specific or subtle symptoms, which can be overlooked or misattributed, leading to delays in diagnosis. These delays can significantly limit treatment options and adversely affect patient outcomes.
The report also draws attention to the continued underuse of biopsy, which is currently offered to fewer than one third of patients, a decline of 5% compared with the previous year. Biopsy plays a crucial role in ensuring accurate diagnosis and in preventing unnecessary surgical intervention.
As clinicians, we have a responsibility not only to diagnose and treat, but also to direct patients to trusted organisations such as Kidney Cancer UK, which provide high-quality information and essential support to help patients and their families navigate the physical and emotional challenges of a kidney cancer diagnosis.
Malcolm Packer, Chief Executive Officer at Kidney Cancer UK, says:
These findings highlight a stark and urgent reality: there are too many people are being diagnosed with kidney cancer at stage 3 and 4. This isn’t just a clinical issue – it’s a human one, with devastating consequences for treatment options, quality of life, and survival. Because symptoms are often vague or entirely absent, patients can feel dismissed or overlooked long before they receive the care they need. That must change.
Once the NICE guidelines we worked so hard to bring to fruition are published, the healthcare professional community at all levels should embrace them and work together to make them work and improve patients pathway, quality of life and improve survival chances.
The whole team at Kidney Cancer UK, are committed to ensuring no one faces a diagnosis alone or unsupported. Our free Support Line, counselling services, and patient resources are designed to provide clarity, reliable information reassurance, and practical help at the moments people need it most. We urge healthcare professionals to signpost patients to our services so they can access the right and best support from day one.
*Our patient survey was produced with financial support from Boston Scientific, Ipsen, Merck, MSD, Pfizer and Telix Pharmaceuticals. Funders had no input into the questions, structure, analysis or content of the survey or this report.
